701 Item-Level Improvements in Inflammatory Bowel Disease Questionnaire Scores in Patients With Ulcerative Colitis Treated With Tofacitinib Induction Therapy

INTRODUCTION: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Significant improvements have been reported in all Inflammatory Bowel Disease Questionnaire (IBDQ) domains for tofacitinib vs placebo (PBO) in patients (pts) with UC in OCTAVE Induction 1 & 2 and OCTAVE Sustain. 1 The effect of tofacitinib on items within each IBDQ domain has not yet been analyzed. METHODS: We examined...